Words from the Chairman

Total Page:16

File Type:pdf, Size:1020Kb

Words from the Chairman Department of Surgery Annual Research Report 2007 Words from the Chairman Surgical Research is part of any contemporary, first class, Department of Surgery and the Beth Israel Deaconess Medical Center is no exception. As the Department grew, so did its research effort and level of funding. Until recently, continual growth in research funding for the Department of Surgery was gratifying indeed. The Department’s research funding from all sources, both NIH and non-NIH, increased from about $10 to more than $21 million annually, during the period of 2002-2005. This growth was impressive, taking the Department from approximately 22nd in the country in total NIH funding, to about 5th or 6th. It is difficult to obtain our exact position amongst NIH-funded Departments of Surgery because this number is calculated by the NIH as a total of all Departments of Surgery at Harvard Medical School, including totals for all Harvard affiliated hospitals. Since 2005, our NIH and other funding for research have been declining. The NIH seems to view its funding for research as discretionary, which is particularly unfortunate given the number of people and planning that must go in to building one’s research holdings, and also the nature of individuals that need to be supported. When there is little money, as there currently is not going to various military needs and other non-discretionary activity, NIH funding declines. Just as others have experienced a downturn in NIH funding, so have we. Our NIH and other funding have diminished, including a reduction in the total dollar amount for each awarded grant and the total number of NIH grants that are funded, including competing renewals of long-standing projects. It is unlikely that this trend will reverse soon and from my conversations with other Department chairs, this downturn is being experienced all over. Nonetheless, the Department of Surgery at the Beth Israel Deaconess Medical Center has a robust research effort and continues to pursue academic productivity as well as research productivity with its excellent faculty. This fact is demonstrated in the following report that summarizes our research effort in 2007. Whether or not the current trend in NIH funding will reverse, is anybody’s guess. At present, it looks like it will not. However, we are grateful for the fine clinical and research faculty that we have and the ability to support first class research that goes on in the Department. We look forward to better days. Josef E. Fischer, MD Chairman, Department of Surgery Beth Israel Deaconess Medical Center William V. McDermott Professor of Surgery Harvard Medical School Beth Israel Deaconess Medical Center i Department of Surgery Annual Research Report 2007 ii Beth Israel Deaconess Medical Center Department of Surgery Annual Research Report 2007 TABLE OF CONTENTS Words from the Chairman................................................................... i Table of Contents.................................................................................... iii Division of Surgical Research.............................................................. 1 Division of Cardiothoracic Surgery Introduction and Division Members................................................. 31 Sidney Levitsky, MD James D. McCully, PhD..................................................................... 33 Frank W. Sellke, MD Cesario Bianchi, MD, PhD................................................................. 37 Division of General Surgery Introduction and Division Members................................................. 45 George L. Blackburn, MD, PhD Jin-Rong Zhou, PhD.......................................................................... 49 Mark P. Callery, MD Charles M. Vollmer, Jr., MD Tara S. Kent, MD……………………………………………………………………. 61 Rosemary B. Duda, MD, MPH.......................................................... 67 Sandra M. Gaston, PhD..................................................................... 71 Susan J. Hagen, PhD......................................................................... 79 Per-Olof Hasselgren, MD, PhD......................................................... 85 Carl J. Hauser, MD, FACS, FCCM..................................................... 91 Daniel B. Jones, MD, MS, FACS........................................................ 93 Wolfgang Junger, MD……………………………………………………………… 105 John T. Mullen, MD, FASC……………………………………………………… 111 Division of Plastic and Reconstructive Surgery Division Members.............................................................................. 113 Divisional Report – Sumner A. Slavin, MD...................................... 115 Beth Israel Deaconess Medical Center iii Department of Surgery Annual Research Report 2007 Division of Podiatry Division Members.............................................................................. 129 Aristidis Veves, MD........................................................................... 131 Division of Transplantation Division Members.............................................................................. 137 Fritz H. Bach, MD.............................................................................. 139 Douglas W. Hanto, MD, PhD............................................................ 141 Seth Karp, MD................................................................................... 145 Maria Koulmanda, MSc, PhD............................................................ 147 Anthony P. Monaco, MD Takashi Maki, MD, PhD.................................................................... 151 Leo E. Otterbein, PhD........................................................................ 153 Terry B. Strom, MD........................................................................... 157 Division of Urology Division Members.............................................................................. 163 Mohamed Arredouani, PhD.............................................................. 165 William C. DeWolf, MD Mike Schopperle, PhD....................................................................... 169 Ann A. Kiessling, PhD Robert C. Eyre, MD Paul Church, MD............................................................................... 173 Martin Sanda, MD............................................................................. 179 Division of Vascular and Endovascular Surgery Division Members.............................................................................. 183 Divisional Report……………………………………………………………………. 185 iv Beth Israel Deaconess Medical Center Department of Surgery Annual Research Report 2007 Division of Surgical Research DIVISION OF SURGICAL RESEARCH Per-Olof Hasselgren, MD, PhD Vice Chairman for Surgical Research Director of Endocrine Surgery George H. A. Clowes, Jr. Professor of Surgery Susan J. Hagen, PhD Associate Director for Surgical Research Associate Professor of Surgery Sabrina Pinder, BS Administrative Coordinator A. Introduction In this section of the Annual Report, we provide an overall description of the goals and responsibilities of the Division of Surgical Research, a summary of research faculty in the Department, funding and publications generated by researchers in the Department of Surgery, and other aspects of research within the Department. More detailed research updates are found for individual members of the different Divisions in subsequent sections of the report. The Division of Surgical Research is an administrative division with an aim to facilitate both basic and clinical research in the Department of Surgery at the Beth Israel Deaconess Medical Center (BIDMC). The Division of Surgical Research is headed by Per-Olof Hasselgren, MD, PhD, who is Vice Chairman for Research in Surgery at BIDMC and the George H.A. Clowes Jr. Professor of Surgery at Harvard Medical School, and Susan J. Hagen, PhD, who is Associate Director for Surgical Research in Surgery at BIDMC and Associate Professor of Surgery at Harvard Medical School. The division is also supported by an administrative coordinator, Ms. Sabrina Pinder. The Division of Surgical Research has the following responsibilities: 1) Pre-award review and approval of all grant submissions in the Department of Surgery. This includes assisting in the process of submission of grant applications and interaction with the BIDMC Office of Sponsored Programs. 2) Management of research space, including laboratory and office space, and shared research equipment. For this, the allocation of research space within the Department is overseen, shared tissue culture facilities are maintained, and the Department is represented at various institutional committees and subcommittees dealing with research space at the BIDMC. 3) Organizing monthly Surgical Research Seminars, open for both clinical and research faculty in the Department as well as other members of the BIDMC community. 4) Preparing the Department of Surgery Annual Research Report. 5) Organizing laboratory and shared equipment maintenance and telecommunications. 6) Supporting and mentoring junior faculty in the establishment of research laboratories. 7) Interacting with and providing information to Surgical Residents who plan to spend time in the research laboratory. 8) Obtaining visas for foreign scholars in Beth Israel Deaconess Medical Center 1 Department of Surgery Annual Research Report 2007 Division of Surgical Research Research and in preparing applications for Harvard Medical School appointments for Research Fellows and Instructors in Surgery Research.
Recommended publications
  • Bedford Stem Cell Research Foundation
    bedford stem cell research foundation ||| The Potential for Miracles ||| Recent advances in stem cell research have raised the hope Founded in 1996, the Bedford Stem Cell of curing diseases once believed to be incurable: heart failure, spinal cord injury, diabetes, Alzheimer’s, Parkinson’s, Research Foundation is a biomedical AIDS. These diseases are the result of the death of specifi c types of cells, such as nerves and the cells in the pancreas institute that exists to conduct stem that produce insulin. For reasons that are not understood, cell and related research for diseases new cells do not automatically replace defective cells in some tissues such as spinal cord, brain and pancreas. and conditions that currently have no Other tissues, such as skin and blood, routinely replace effective methods of treatment or cure. dying cells with new cells recruited from reserve supplies that maintain the potential to become active and multiply when needed. [fi g 1] Such cells are called stem cells. Skin stem cells are examples of adult stem cells, so-called ||| The Foundation ||| because they can become only one type of tissue, e.g. skin. In contrast, cells from early embryos are pluripotent, that Bedford Stem Cell Research Foundation is at the forefront is, they have the potential to become all types of tissues. of stem cell and related research. Founded in 1996, the Experiments with laboratory mice have demonstrated that Foundation has an established community of scientists pluripotent stem cells can replace dead cells in all organs investigating stem cell therapies. Committed to conduct- including the heart, which does not have its own supply of ing ethical research, the Foundation relies on its Ethics stem cells.
    [Show full text]
  • Before the Scientific and Medical Accountability
    BEFORE THE SCIENTIFIC AND MEDICAL ACCOUNTABILITY STANDARDS WORKING GROUP OF THE INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE TO THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE ORGANIZED PURSUANT TO THE CALIFORNIA STEM CELL RESEARCH AND CURES ACT REGULAR MEETING LOCATION: AS INDICATED ON THE AGENDA DATE: JULY 24, 2013 10 A.M. REPORTER: BETH C. DRAIN, CSR CSR. NO. 7152 BRS FILE NO.: 94597 BARRISTERS' REPORTING SERVICE I N D E X ITEM DESCRIPTION PAGE NO. CALL TO ORDER 3 ROLL CALL 3 CONSIDERATION OF IMTERIM REGULATION REGARDING USE OF STEM CELL LINES PUBLIC COMMENT 2 160 S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: [email protected] BARRISTERS' REPORTING SERVICE 1 SAN FRANCISCO, CALIFORNIA; JULY 24, 2013 2 12 P.M. 3 4 DR. LOMAX: WHY DON'T WE START WITH ROLL. 5 IT'S ONLY ONE PERSON WHO'S RESPONDED THAT I KNOW IS 6 NOT HERE ON-SITE, BUT HOPEFULLY TED PETERS WILL BE 7 ARRIVING SHORTLY. 8 SHERRY LANSING. 9 MS. LANSING: HERE. 10 DR. LOMAX: BERNARD LO. 11 CHAIRMAN LO: HERE. 12 DR. LOMAX: JEFF BODKIN. 13 DR. BODKIN: HERE. 14 DR. LOMAX: MARCY FEIT. TIM KAMP. 15 DR. KAMP: YES. 16 DR. LOMAX: ANN KIESSLING. KEN OLDEN. 17 FRANCISCO PRIETO. 18 DR. PRIETO: HERE. 19 DR. LOMAX: TED PETERS. 20 DR. PETERS: TED PETERS IS HERE, YES, ON 21 THE PHONE. 22 DR. LOMAX: OH, TERRIFIC. DOROTHY 23 ROBERTS. 24 DR. ROBERTS: YES. I'M HERE ON THE PHONE. 25 DR. LOMAX: TERRIFIC. 3 160 S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: [email protected] BARRISTERS' REPORTING SERVICE 1 JEFF SHEEHY.
    [Show full text]
  • Drug Shortages Prompt Doctors, Societies to Consider Non-Profit
    Vol. 37 No. 33 Sept. 9, 2011 SPECIAL ISSUE © Copyright 2011 The Cancer Letter Inc. All rights reserved. Price $395 Per Year. To subscribe, call 800-513-7042 or visit www.cancerletter.com. PO Box 9905 Washington DC 20016 Telephone 202-362-1809 Drug Shortages Prompt Doctors, Societies To Consider Non-Profit Pharma Company By Paul Goldberg The market hasn’t been working very well in producing enough generic drugs lately. The government hasn’t done much to correct the problem, either. FDA Approvals: This year alone, as many as 180 different generic drugs have been Agency Approves affected by shortages. In oncology, drugs in short supply include cytarabine, daunorubicin, Two New Pairs of doxorubicin, leucovorin, 5-FU, cisplatin and paclitaxel. Drugs and To solve the problem, several players in oncology are considering Diagnostic Tests novel ways to produce generic drugs, as well as drugs that have no chance . Page 8 to become blockbusters, or for that matter, even modest sellers. One group of prominent oncologists is circulating a proposal—and trying Obituaries: (Continued to page 2) Fritz Bach, 77 The Duke Scandal: William Wolff, 94 Duke Researchers Retract Paper From Blood; . Page 9 Dozens of Retractions of Potti's Work Expected By Conor Hale In Brief: The journal Blood published a retraction by a group of scientists Gilbertson Named including former Duke University researcher Anil Potti—continuing a cascade Director of St. Jude; of retractions of the group’s work over the past several months. Lowe To Be Chief of Additional retractions of papers published by Potti during his time at MSKCC Geoffrey Duke are in the works, university officials said.
    [Show full text]
  • Transplant Chronicles
    Transplant Chronicles Volume 6 A publication for transplant recipients of all organs and their families, Number 1 published by the National Kidney Foundation, Inc. ow could I look down into believed we had a chance, and I hisH crib one more time knowing their responses were “like finding God would take him from me? a needle in a haystack,” or like This is my first grandchild who I “winning the lottery.” Not only are Hurt wanted so very much. blood type and cross match very important, the size of the donor My Cody was born with a heart plays a big part, too. His hypoplastic left heart, meaning he little chest would only accommo- So Bad only had two chambers instead of date a heart maybe four months the normal four. He was born at older than Cody, and his time was by Joyce Rasmussen Unity Hospital, transferred to running out. Children's Hospital, then a week later transferred to the University Cody already had lived longer of Minnesota, where for five weeks than the doctors thought, but we hoped and prayed for a heart soon it would be too late. I was transplant. Soon I was filled with trying to keep my kids’ emotions doubts and anger, which aroused down so that when the time came many questions. How could this for us to say goodbye to our dear beautiful child be created with little Cody, we could thank God only half a heart? His heart for the short time we had with monitor told me he heard and him and accept his decision.
    [Show full text]
  • Experience with 13 Segmental Pancreas Transplants in Cyclosporine-Treated Diabetic Patients Using Ethibloc for Duct Obliteration (Surgical Aspects) W
    Transplantation Proceedings An Official Publication of The Transplantation Society The Latin American Transplantation Society The Japan Society for Transplantation The European Society for Organ Transplantation The British Transplantation Society The Canadian Transplantation Society The Transplantation Society of Australia and New Zealand The Scandinavian Transplantation Society EDITORIAL STAFF Felix T. Rapaport, M.D., Editor-in-Chief, Stony Brook, N.Y. Jean Dausset, European Editor, Radoslav J. Bachvaroff, Associate Editor, Paris, France Stony Brook, Ν. Y. David Anaise, Assistant Editor, Robert J. Corry, Assistant Editor (Clinical) Stony Brook, Ν. Y. Iowa City, Iowa Phillip R. Casson, Assistant Editor Wayne C. Waltzer, Assistant Editor (Abstracts) New York, Ν. Y. Stony Brook, Ν. Y. ADVISORY BOARD Fritz Bach, Minneapolis, Minn. Felix Milgrom, Buffalo, N.Y. Hans Balner, Rijswijk, Holland Anthony P. Monaco, Boston, Mass. J. Richard Batchelor, England John S. Najarian, Minneapolis, Minn. R. E. Billingham, Dallas, Tex. G. J. V. Nossal, Victoria, Australia Leslie Brent, London, England Kendrick A. Porter, London, England Felix Cantarovich, Buenos Aires, Argentina Keith Reemtsma, New York, Ν. Y. Raftaello Cortesini, Rome, Italy Jorge Rodo, Buenos Aires, Argentina Eli A. Friedman, Brooklyn, N.Y. Paul S. Russell, Boston, Mass. Robert A. Good, Oklahoma City. Okla. Kenneth W. Seil, Bethesda, Md. Jean Hamburger, Paris, France Maurice Slapak, Portsmouth, England Milan Hasek, Prague, Czechoslovakia Thomas E. Starzl, Pittsburgh, Pa. George Klein, Stockholm, Sweden Paul Terasaki, Los Angeles, Calif. H. Sherwood Lawrence, New York, N.Y. Jules Traeger, Lyon, France Η. M. Lee, Richmond, Va. Dick V. Van Bekkum, Rijswijk, Holland Richard R. Lower, Richmond, Va. Jon J. Van Rood, Leiden, Netherlands Robert McCluskey, Boston, Mass.
    [Show full text]
  • Jon Van Rood the Pioneer and His Personal View on the Early
    Transplant Immunology 52 (2019) 1–26 Contents lists available at ScienceDirect Transplant Immunology journal homepage: www.elsevier.com/locate/trim Review Jon van Rood: The pioneer and his personal view on the early developments T of HLA and immunogenetics ⁎ Martine J. Jagera, , Anneke Brandb, Frans H.J. Claasc a Dept. of Ophthalmology, LUMC, Leiden, The Netherlands b Sanquin, Leiden, The Netherlands c Dept. of Immunohematology and Blood Transfusion, LUMC, Leiden, The Netherlands ABSTRACT A single observation in a patient with an unusual transfusion reaction led to a life-long fascination with immunogenetics, and a strong wish to improve the care for patients needing a transplantation. In 2017, Jon van Rood, one of the pioneers in the field of HLA and immunogenetics of transplantation, passed away. Several obituaries have appeared describing some of the highlights of his career. However, the details of the early developments leading among others to the routine use of HLA as an important parameter for donor selection in organ- and hematopoietic stem cell transplantation are largely unknown to the community. After his retirement as Chair of the Department of Immunohaematology and Blood Transfusion (IHB) in 1991, Jon van Rood wrote regularly in the “Crosstalk”, the departmental journal, and gave his personal view on the history of the discovery and implications of HLA. These autobiographic descriptions were originally written in Dutch and have been translated, while texts from other sources and the relevant references have been added to illustrate the historical perspective. This special issue of Transplant Immunology combines the autobiographic part, Jon's own version of the history, with other facts of his scientific life and the impact of his findings on the field of clinical transplantation.
    [Show full text]
  • BEDFORD STEM CELL RESEARCH FOUNDATION Massachusetts 501(C)(3) Not for Profit Organization P: 617-281-7902 E: [email protected] W
    BEDFORD STEM CELL RESEARCH FOUNDATION Massachusetts 501(c)(3) not for profit organization P: 617-281-7902 E: [email protected] W: www.bedfordresearch.org The Testis: a source of stem cells for all men? Could the newly discovered “testis stem cells” be as versatile as embryonic stem cells? Bedford is launching a major research initiative to find out. A major barrier to progress in stem cell avoid the rejection that occurs if therapies is that, similar to organ transferred cells are not a perfect tissue transplantation, the body rejects cells match to the patient’s own cells. that are not a good match for the patient. Surprisingly, stem cells from testis may Dr. Martin Dym’s research team at $280k offer a solution. In 2008, a German team Georgetown University estimates reported that they successfully derived approximately 1 in 100,000 testis stem $250K pluripotent stem cells from adult mouse cells may be pluripotent. For several $200k testis. Because of their unique ability to decades, it has been known that sperm become any type of cell in the body, are abundantly produced (billions per $150k pluripotent stem cells hold the promise of week) in the adult male testis for life, cures to many conditions, from diabetes and that the sperm arise from “sperm $136k to spinal cord diseases. Then in 2009, stem cells” termed spermatogonia. two U.S. research teams discovered However, the new reports indicate that $100k pluripotent stem cells in human testis. in addition to the spermatogonia, there $50k are pluripotent stem cells in the testis. To If pluripotent stem follow up these exciting reports, Bedford $0 cells can be derived Research scientists have launched a new from every human research initiative to answer several testis, it could launch a important questions: (1) Can stem cells Mouse Testis new era in stem cell be derived from the testis of all men? Stem Cells research.
    [Show full text]
  • M.Sc Ist Yr MICROBIOLOGY a Bottle of Wine Contains More Philosophy Than All the Books in the World
    M.Sc Ist yr MICROBIOLOGY A bottle of wine contains more philosophy than all the books in the world. -Louis Pasteur JANUARY 2022 M T W T F S S Ferdinand Cohn (Founder of 31 1 2 Bacteriology and Microbiology) Global Family Day 3 4 5 6 7 8 9 Richard Rebecca Har Michael Craighill Gobind Krause Lancefield Khorana Rebecca Craighill Lancefield (well known for serological classification of β- hemolytic streptococcal bacteria) 10 11 12 13 14 15 16 National Indian Youth Day Army Day 17 18 19 20 21 22 23 Bacillus cereus Bacillus cereus is a facultatively anaerobic, toxin producing, gram- positive bacteria that canm be found in siol vegetation anf even food. This may cause two types of intestinal illness, one diarrheal, and 24 25 26 27 28 29 30 one causing nausea and vomiting.It Ferdinand National Heinrich World can quickly multiply at room Kohn Tourism Anton de Leprosy temperature. B.cereus has also been National Girl Day Bary Day Child Day Republic implicated in infections of the eye, respiratory tracts , and in wounds. International Day B.cereus and other members of Day of Education bacillus are not easily killed by alcohol,they have been known to World Leprosy Day – 30th JAUNARY: World Leprosy colonize distilled liquors and Day is observed internationally every year on the last Sunday of alcohol soaked swabs and pads in January to increase the public awareness of leprosy or Hansen's numbers sufficient to cause Disease. This date was chosen by French humanitarian Raoul infection. Follereau as a tribute to the life of Mahatma Gandhi who had compassion for people afflicted with leprosy.
    [Show full text]
  • Ann Kiessling Oral History Interview, “Reflections on Oregon Roots”, June 13, 2014 Page 2 of 11
    Ann Kiessling Oral History Interview, June 13, 2014 Title “Reflections on Oregon Roots” Date June 13, 2014 Location Valley Library, Oregon State University. Summary In the interview, Kiessling speaks of her connections with the state of Oregon and OSU. In so doing, she reflects on the academic path that led to her arrival at OSU as a doctoral candidate in 1967, a path that included her earning a degree in nursing as a tool for funding further schooling. She discusses her association with her major professor at OSU, Dr. George Beaudreau, and the work that she conducted in his laboratory, investigating the relationship between viruses and cancer. She shares her memories of her academic progression at Oregon State as well as campus and community life in the late 1960s and early 1970s. She likewise notes the impact that OSU made on the next stages of her career. The remainder of the interview is chiefly devoted to Kiessling's recollections of her broader ties to the state, including her upbringing in Klamath Falls and the eight years that she spent on faculty at Oregon Health Sciences University. This interview was conducted in connection with Kiessling's June 2014 visit to Corvallis, during which time she delivered the Commencement Address at OSU's graduation exercises. Interviewee Ann Kiessling Interviewer Chris Petersen Website http://scarc.library.oregonstate.edu/oh150/kiessling/ PDF Created November 16, 2017 Ann Kiessling Oral History Interview, “Reflections on Oregon Roots”, June 13, 2014 Page 2 of 11 Transcript Chris Petersen: Okay, if you could please introduce yourself with your name and today's date, and our location? Anne Kiessling: I'm Ann Kiessling, and this is June 13th, 2014, and we are somewhere in the basement of the OSU library.
    [Show full text]
  • Organ Transplantation: the Thice S of Consequences Elora J
    The Linacre Quarterly Volume 69 | Number 2 Article 1 May 2002 Organ Transplantation: The thicE s of Consequences Elora J. Weringer Follow this and additional works at: http://epublications.marquette.edu/lnq Recommended Citation Weringer, Elora J. (2002) "Organ Transplantation: The thicE s of Consequences," The Linacre Quarterly: Vol. 69: No. 2, Article 1. Available at: http://epublications.marquette.edu/lnq/vol69/iss2/1 Organ Transplantation: The Ethics of Consequences by Elora J. Weringer, Ph.D. The author has been Senior Research Investigator for Pfizer, Inc. There, she conducted drug discovery research programs in immunology of transplantation and autoimmune diseases. Organ allograft transplantation, as a life-saving procedure for those in end­ stage irreversible organ failure, has benefited and progressed because of the innovations in clinical and pharmacological research. Advancing the early studies in transplantation Dr. Joseph Murray and colleagues were among the first to use pharmacological agents in transplant patients. I Initially, the agents used to enhance graft acceptance were either cytotoxic and suppressed all dividing cells in the body or cytostatic, such as the steroids, which attenuated the immune cells.2 These drugs, however, were non-specific, had unpredictable efficacy, and usually grave side effects. As knowledge and understanding of the immune system unfolded, so did new concepts for designing better methods of preventing organ allograft rejection. Early on, attention centered on the theory of graft "foreignness", but in the era of molecular biology, it has expanded to include the intricacies of the intracellular environment and the events, which comprise the recognition, activation and cellular proliferation of the immune response.
    [Show full text]
  • Transplantation Is Not Enough..., Or on the Concept of Xenotransplantation
    STUDIES IN LOGIC, GRAMMAR AND RHETORIC 52 (65) 2017 DOI: 10.1515/slgr-2017-0045 Ewa M. Guzik-Makaruk University of Bialystok, Faculty of Law Marta M. Perkowska University of Bialystok, Faculty of Pedagogy and Psychology TRANSPLANTATION IS NOT ENOUGH..., OR ON THE CONCEPT OF XENOTRANSPLANTATION Abstract. The paper presents the emergence of the concept of xenotransplan- tation which is a relatively new issue in the literature on the subject. It is due to the fact that transplants of animal organs are currently in the experi- mental phase. The main current problem of transplantology is the shortage of organs; hence, the search for new solutions has become an everyday challenge. If a way for the human body to tolerate animal organs could be found, transplant medicine and humanity would be in a completely different place. The authors introduce the concepts of transplantation and xenotransplantation and their origins, then they raise ethical issues related to this type of organ transplanta- tion. Finally, the authors conclude that xenotransplantations have a chance to be “incorporated” (back again) in the “transplants” category when the exper- imental phase of xenotransplantation shifts to the implementation stage. Time will tell whether it will be possible. Keywords: transplantation, xenotransplantation, heterotransplantation, medical experiment. Introduction The current key problem of transplantology is the deficiency of organs. By virtue of the fact that “nature abhors a vacuum” and it initiates on its own various actions to fill that void, people, drawing on familiar ways of coping in such cases, as for example filling the void in their own stomachs, undertake the idea of filling other “voids” in their own bodies, for example in the place of a sick kidney, with parts of animal bodies.
    [Show full text]
  • Research Biotechnology Clarify the Ethics of Stem Cell a Natural Stem
    Downloaded from jme.bmjjournals.com on 8 May 2006 A natural stem cell therapy? How novel findings and biotechnology clarify the ethics of stem cell research P Patel J. Med. Ethics 2006;32;235-239 doi:10.1136/jme.2005.012096 Updated information and services can be found at: http://jme.bmjjournals.com/cgi/content/full/32/4/235 These include: References This article cites 18 articles, 7 of which can be accessed free at: http://jme.bmjjournals.com/cgi/content/full/32/4/235#BIBL Rapid responses One rapid response has been posted to this article, which you can access for free at: http://jme.bmjjournals.com/cgi/content/full/32/4/235#responses You can respond to this article at: http://jme.bmjjournals.com/cgi/eletter-submit/32/4/235 Email alerting Receive free email alerts when new articles cite this article - sign up in the box at the service top right corner of the article Topic collections Articles on similar topics can be found in the following collections Other Ethics (1359 articles) Research and publication ethics (478 articles) Notes To order reprints of this article go to: http://www.bmjjournals.com/cgi/reprintform To subscribe to Journal of Medical Ethics go to: http://www.bmjjournals.com/subscriptions/ Downloaded from jme.bmjjournals.com on 8 May 2006 235 RESEARCH ETHICS A natural stem cell therapy? How novel findings and biotechnology clarify the ethics of stem cell research P Patel ............................................................................................................................... J Med Ethics 2006;32:235–239. doi: 10.1136/jme.2005.012096 The natural replacement of damaged cells by stem cells occurs actively and often in adult tissues, especially rapidly dividing cells such as blood cells.
    [Show full text]